ASX biotech share rockets 47% on 'landmark decision'

Australia just became the first country to allow ecstasy and magic mushrooms to be used to treat mental disorders.

| More on:
Woman looks amazed and shocked as she looks at her laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Late Friday, Australia became the first country in the world to recognise ecstasy and magic mushrooms as medical treatments.

Officially, the drugs approved for use are 3,4-methylenedioxy-methamphetamine (MDMA) and psilocybin. 

The Therapeutic Goods Administration made the surprise announcement that both would be allowed to be prescribed by psychiatrists from July onwards to treat mental disorders.

The milestone triggered investors to pile onto one particular ASX stock on Monday morning.

'The only ASX company' in position to take advantage of TGA decision

Furious demand saw the share price for neuroscience and mental health biotech Emyria Ltd (ASX: EMD) rocket 47.4% upwards after just 38 minutes of trading on Monday.

The company itself had recognised the TGA announcement before the session, calling it a "landmark" decision in a statement to the ASX.

"Emyria… is well positioned to accelerate patient access to MDMA-assisted therapies following recent TGA regulation changes."

While the TGA was mulling over the decision, Emyria had set up "a network of clinical partners", formed a supply chain and "developed a comprehensive Phase 2B clinical trial protocol for MDMA-assisted therapy".

According to Emyria managing director Dr Michael Winlo, the "mental health crisis" globally continues to bear tremendous social and monetary costs.

"Which is why the TGA's move to reschedule MDMA and psilocybin is timely and world-leading," he said.

"Emyria is well-prepared to support the safe provision of MDMA-assisted therapies under this new change as the only ASX company with a clinical service specialising in unregistered medicines and real-world data generation."

He added that the company has "also developed a comprehensive MDMA-assisted therapy protocol that can now support specialists".

Drug discovery program

Emyria also has fires burning for related products. It has launched an "MDMA-inspired drug discovery" program in conjunction with the University of Western Australia.

"The partnership has now developed, screened and filed IP for over 140 proprietary, neurologically active and novel MDMA-like compounds with the potential to become registered treatments for a range of neuropsychiatric disorders and new psychedelic treatments."

The Emyria board stated that the TGA decision would create a pathway for "registration and reimbursement for MDMA and its analogues".

"We believe the TGA's decision will allow Emyria – and its partners – to build a stronger evidence base for treating mental health conditions with psychedelics and make a large and positive impact for patients globally," said Winlo.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young office worker is surrounded by peers who are clapping and congratulating her.
Healthcare Shares

Up 140% in 2024, here's why this ASX 200 healthcare stock is making news again today

It’s yet another positive update for this stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 ASX healthcare shares surging on big news

The ASX healthcare sector is higher on Tuesday and these stocks are among the strongest performers.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The pros and cons of buying CSL shares right now

It’s an interesting time to consider this healthcare giant.

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »